Neuroethics and the FDA Approval of Aducanumab First, Do No Harm

In this episode, Karishma interviews Dr. Jason Karlawish, Professor of Medicine, Medical Ethics and Health Policy, and Neurology at the University of Pennsylvania Perelman School of Medicine. We discuss the bioethics of aging and Alzheimer’s as well as the recent controversial FDA approval of aducanumab to help treat Alzheimer’s disease. We explore issues from the implications of aducanumab’s approval on care and treatment of patients with Alzheimer’s, how it will impact prescribing habits, and the shared decision-making process between providers and the patient and their caregivers.